4.7 Article

Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts

期刊

RHEUMATOLOGY
卷 49, 期 2, 页码 259-263

出版社

OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kep371

关键词

alpha-Smooth muscle actin; Myofibroblast; Rosiglitazone; Connective tissue growth factor; CCN2; Type I collagen

资金

  1. Canadian Foundation for Innovation
  2. Canadian Institutes of Health Research
  3. Ontario Thoracic Society
  4. Arthritis Research Campaign
  5. Reynaud's and Scleroderma Association

向作者/读者索取更多资源

Objective. The transcription factor peroxisome proliferator-activated receptor ( PPAR)-gamma plays an important role in controlling cell differentiation. The aim of the present study was to examine whether PPAR-gamma expression was reduced in skin scleroderma fibroblasts and whether PPAR-gamma agonists could suppress the persistent fibrotic phenotype of skin scleroderma fibroblasts. Methods. Dermal fibroblasts were isolated from site-, age- and sex-matched healthy individuals and lesional areas of individuals with dcSSc. Western blot and collagen gel contraction analyses were used to detect protein expression in the presence or absence of the PPAR-gamma agonist rosiglitazone. Results. PPAR-gamma expression was reduced in dcSSc fibroblasts. The PPAR-gamma agonist rosiglitazone alleviated the persistent fibrotic phenotype of dcSSc fibroblasts. Conclusion. Rosiglitazone may alleviate the extent of fibrosis in dcSSc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Rheumatology

Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma

Bodoor Yaseen, Henry Lopez, Zeinab Taki, Sara Zafar, Henrique Rosario, Bahja Ahmed Abdi, Shivanee Vigneswaran, Fiona Xing, Nikita Arumalla, Simon Black, Sara Ahmad, Kimti Kumar, Rabia Gul, Laura Scolamiero, Sian Morris, Alex Bowman, Anna Stainer, Alexandra Rice, Carmel Stock, Elisabetta Renzoni, Christopher P. Denton, Cristina Venturini, Max Brown, Steven O'Reilly, Richard Stratton

RHEUMATOLOGY (2020)

Article Rheumatology

Pathogenic Activation of Mesenchymal Stem Cells Is Induced by the Disease Microenvironment in Systemic Sclerosis

Zeinab Taki, Elena Gostjeva, William Thilly, Bodoor Yaseen, Henry Lopez, Maria Mirza, Zainab Hassuji, Shivanee Vigneswaran, Bahja Ahmed Abdi, Amy Hart, Nikita Arumalla, Gemma Thomas, Christopher P. Denton, Yasir Suleman, Huan Liu, Cristina Venturini, Steven O'Reilly, Shiwen Xu, Richard Stratton

ARTHRITIS & RHEUMATOLOGY (2020)

Article Dermatology

Wnt antagonist DKK-1 levels in systemic sclerosis are lower in skin but not in blood and are regulated by microRNA33a-3p

John Henderson, Stefan Pryzborski, Richard Stratton, Steven O'Reilly

Summary: DKK-1 is reduced in SSc skin and fibroblasts but not in the circulation of patients. MicroRNA33a-3p epigenetically regulates DKK-1 levels and is significantly reduced in SSc cells and tissues. Restoring DKK-1 levels through epigenetic means could be a therapeutic target in systemic sclerosis.

EXPERIMENTAL DERMATOLOGY (2021)

Editorial Material Rheumatology

Pulmonary Limited ANCA-Associated Vasculitis Mimicking COVID-19

Carine J. Moezinia, Antonio Ji-Xu, Animesh Singh, Richard Stratton

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2020)

Article Biochemistry & Molecular Biology

microRNA27a-3p mediates reduction of the Wnt antagonist sFRP-1 in systemic sclerosis

John Henderson, Sarah Wilkinson, Stefan Przyborski, Richard Stratton, Steven O'Reilly

Summary: Systemic Sclerosis (SSc) is an autoimmune connective tissue disease that causes skin and lung fibrosis. The Wnt pathway is upregulated in SSc and promotes fibrosis through activation of canonical Wnt signaling. sFRP-1, a Wnt antagonist, acts as a negative regulator of Wnt signaling in the context of SSc. Serum levels of sFRP-1 were found to be significantly reduced in patients with early diffuse SSc, and this reduction was regulated by microRNA27a-3p, indicating a direct regulatory mechanism.

EPIGENETICS (2021)

Editorial Material Rheumatology

Ochronotic arthropathy in alkaptonuria

M. Adam Ali, Richard Stratton

RHEUMATOLOGY (2021)

Letter Rheumatology

First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors

Arianna E. Azari, Richard Stratton, Animesh Singh

RHEUMATOLOGY (2021)

Article Cell Biology

Verteporfin inhibits the persistent fibrotic phenotype of lesional scleroderma dermal fibroblasts

Xu Shi-Wen, Michael Racanelli, Aaisham Ali, Amara Simon, Katherine Quesnel, Richard J. Stratton, Andrew Leask

Summary: Fibrosis is perpetuated by a signaling loop involving myofibroblasts and the extracellular matrix. YAP1 plays a crucial role in regulating the expression of matricellular proteins and the effect of YAP inhibitors on profibrotic gene expression is a subject of study. The selective YAP inhibitor VP shows potential in reducing fibrogenic gene expression and may offer a novel method for treating fibrosis.

JOURNAL OF CELL COMMUNICATION AND SIGNALING (2021)

Article Infectious Diseases

COVID-19 in Northeast Bosnia and Herzegovina and patient's length of hospitalization

Alma Trnacevic, Amer Mujkanovic, Noura Al-Salloum, Amra Sakusic, Emir Trnacevic, Emir Jusufovic, Fatima Hukic, Rahima Jahic, Richard Stratton

Summary: This study analyzed the data of the first cohort of COVID-19 patients in B&H, finding that factors such as BMI greater than 25, comorbidities, elevated creatinine, and O2 saturation less than 95% may lead to prolonged hospitalization. Furthermore, the risk factors for COVID-19 patients in B&H do not differ from those reported in other countries.

BMC INFECTIOUS DISEASES (2021)

Article Cell Biology

The Cell-Permeable Derivative of the Immunoregulatory Metabolite Itaconate, 4-Octyl Itaconate, Is Anti-Fibrotic in Systemic Sclerosis

John Henderson, Sharadha Dayalan Naidu, Albena T. Dinkova-Kostova, Stefan Przyborski, Richard Stratton, Steven O'Reilly

Summary: The study demonstrates that 4-octyl itaconate (4-OI) can reduce collagen levels in systemic sclerosis (SSc) dermal fibroblasts and exert its effects through activation of Nrf2 and its target genes in antioxidant response. Additionally, 4-OI also decreases inflammatory cytokine release and alleviates TGF-beta 1-induced collagen and ROS production in dermal fibroblasts. These findings suggest that 4-OI may be a potential therapeutic option for intractable diseases.
Article Cell Biology

Bone Morphogenetic Protein Antagonist Gremlin-1 Increases Myofibroblast Transition in Dermal Fibroblasts: Implications for Systemic Sclerosis

Laura Duffy, John Henderson, Max Brown, Stefan Pryzborski, Nicola Fullard, Lena Summa, Jorg H. W. Distler, Richard Stratton, Steven O'Reilly

Summary: The study revealed that overexpression of Gremlin-1 activates quiescent cells to myofibroblasts and leads to functional effects. Gremlin-1 induces this process by increasing TGF-beta 1 levels and SBE luciferase activity. Inhibition of Gremlin-1 reduces collagen levels, indicating its key role in systemic sclerosis.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Editorial Material Emergency Medicine

A Woman With Fatigue and Orthostatic Hypotension Who Had Run Out of Steroids

M. Adam Ali, Richard Stratton

ANNALS OF EMERGENCY MEDICINE (2021)

Editorial Material Medicine, General & Internal

Bullous Sweet's syndrome in rheumatoid arthritis after streptococcal pharyngitis

Carolina Teles, Richard Stratton

CLINICAL MEDICINE (2023)

Article Cell Biology

A Novel CD206 Targeting Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice

Anghesom Ghebremedhin, Ahmad Bin Salam, Benjamin Adu-Addai, Steve Noonan, Richard Stratton, Md Shakir Uddin Ahmed, Chandra Khantwal, George R. Martin, Huixian Lin, Chris Andrews, Balasubramanyam Karanam, Udo Rudloff, Henry Lopez, Jesse Jaynes, Clayton Yates

Summary: In this study, a synthetic peptide called RP-832c was used to target CD206 receptor on M2-like macrophages and reduce pulmonary fibrosis. RP-832c showed selective binding to M2 macrophages in vitro, resulting in decreased CD206 expression and increased TNF-alpha release. Furthermore, RP-832c significantly reduced fibrosis in mouse lungs and decreased inflammatory cytokines and fibrosis markers. Compared to FDA-approved drugs, RP-832c exhibited similar or greater efficacy in reducing fibrosis without apparent toxicities. These findings suggest the therapeutic potential of RP-832c for patients with pulmonary fibrosis.
Article Cell Biology

Metabolic reprogramming of glycolysis and glutamine metabolism are key events in myofibroblast transition in systemic sclerosis pathogenesis

John Henderson, Laura Duffy, Richard Stratton, Dianne Ford, Steven O'Reilly

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)

暂无数据